KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Emergent BioSolutions (EBS) Amortization - Deferred Charges (2016 - 2017)

Historic Amortization - Deferred Charges for Emergent BioSolutions (EBS) over the last 3 years, with Q4 2017 value amounting to $95000.0.

  • Emergent BioSolutions' Amortization - Deferred Charges fell 5518.87% to $95000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $680000.0, marking a year-over-year increase of 1147.54%. This contributed to the annual value of $681000.0 for FY2017, which is 1280.41% down from last year.
  • Per Emergent BioSolutions' latest filing, its Amortization - Deferred Charges stood at $95000.0 for Q4 2017, which was down 5518.87% from $195000.0 recorded in Q3 2017.
  • In the past 5 years, Emergent BioSolutions' Amortization - Deferred Charges registered a high of $215000.0 during Q3 2015, and its lowest value of $95000.0 during Q4 2017.
  • For the 3-year period, Emergent BioSolutions' Amortization - Deferred Charges averaged around $189111.1, with its median value being $195000.0 (2017).
  • Its Amortization - Deferred Charges has fluctuated over the past 5 years, first surged by 761.42% in 2016, then tumbled by 5518.87% in 2017.
  • Quarter analysis of 3 years shows Emergent BioSolutions' Amortization - Deferred Charges stood at $197000.0 in 2015, then rose by 7.61% to $212000.0 in 2016, then crashed by 55.19% to $95000.0 in 2017.
  • Its last three reported values are $95000.0 in Q4 2017, $195000.0 for Q3 2017, and $195000.0 during Q2 2017.